Top

Published in:

01-07-2008 | Alzheimer's Disease and Related Disorders - Short Communication

Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

Authors: R. Ghidoni, L. Benussi, M. Glionna, M. Franzoni, D. Geroldi, E. Emanuele, G. Binetti

Published in: Journal of Neural Transmission | Issue 7/2008

Abstract

Growing evidence advanced the idea that the soluble form of the receptor for advanced glycation end-products (sRAGE) might serve as a risk marker for several disorders including Alzheimer disease. We found a reduced level of circulating sRAGE in patients with mild cognitive impairment (MCI). The reduction of sRAGE in MCI, as well as the anticipation of the disease in patients with the lowest sRAGE levels (≤225 pg/ml), suggest a role of the RAGE axis in the pathogenesis of the disease.

Arancio O, Zhang HP, Chen X et al (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096–4105PubMedCrossRef

Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–886PubMedCrossRef

Bucciarelli LG, Wendt T, Rong L et al (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117–1128PubMedCrossRef

Emanuele E, D’Angelo A, Tomaino C et al (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62:1734–1736PubMedCrossRef

Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMedCrossRef

Geroldi D, Falcone C, Emanuele E (2006a) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13:1971–1978PubMedCrossRef

Geroldi D, Falcone C, Minoretti P et al (2006b) High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54:1149–1150PubMedCrossRef

Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548PubMed

Lue LF, Yan SD, Stern DM et al (2005) Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord 4:249–266PubMedCrossRef

McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMed

Petersen RC, Doody R, Kurz A et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992PubMedCrossRef

Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308PubMedCrossRef

Yan SD, Roher A, Chaney M et al (2000) Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim Biophys Acta 1502:145–157PubMed

Title: Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment
Authors: R. Ghidoni
L. Benussi
M. Glionna
M. Franzoni
D. Geroldi
E. Emanuele
G. Binetti
Publication date: 01-07-2008
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 7/2008
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-008-0069-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2008

MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats

Microarray expression analysis reveals genetic pathways implicated in C621 synphilin-1-mediated toxicity

Transmission disequilibrium studies in early onset of obsessive–compulsive disorder for polymorphisms in genes of the dopaminergic system

A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity

Neurotrophin and neuropeptide expression in mouse brain is regulated by knockout of the norepinephrine transporter

MKC-231, a choline-uptake enhancer: (1) long-lasting cognitive improvement after repeated administration in AF64A-treated rats